INTS Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.379

Open

0.379

VWAP

0.00

Vol

361.00K

Mkt Cap

23.00M

Low

0.367

Amount

134.00K

EV/EBITDA(TTM)

--

Total Shares

60.00M

EV

16.00M

EV/OCF(TTM)

--

P/S(TTM)

--

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.

Show More

Events Timeline

(ET)

2026-01-13

08:00:00

Intensity Plans to Raise Capital in 2026 to Advance Clinical Studies

2025-12-11 (ET)

2025-12-11

08:00:00

Intensity Therapeutics Presents Research Findings at San Antonio Breast Cancer Symposium

2025-11-06 (ET)

2025-11-06

16:45:11

Intensity Therapeutics announces Q3 earnings per share of 6 cents compared to a loss of 25 cents last year.

2025-10-31 (ET)

2025-10-31

08:07:52

Intensity Therapeutics sets price at 80 cents for 5 million shares in registered direct offering

2025-10-30 (ET)

2025-10-30

07:39:45

Study Highlights Antitumor Effects of Intensity Therapeutics' INT230-6

2025-09-10 (ET)

2025-09-10

07:49:08

Intensity Therapeutics halts enrollment of new patients in the INVINCIBLE-4 trial.

2025-08-12 (ET)

2025-08-12

07:48:47

Intensity Therapeutics regains Nasdaq compliance

News

an image of PRnewswire

01-13PRnewswire

Intensity Therapeutics Highlights 2025 Milestones and 2026 Strategic Priorities

an image of NASDAQ.COM

2025-12-15NASDAQ.COM

Everything You Should Know About the Rating Upgrade to Buy for Intensity Therapeutics Inc. (INTS)

an image of Newsfilter

2025-12-05Newsfilter

Intensity Therapeutics Receives 180-Day Nasdaq Compliance Extension

an image of PRnewswire

2025-12-05PRnewswire

Intensity Therapeutics Secures 180-Day Nasdaq Compliance Extension

an image of SeekingAlpha

2025-12-05SeekingAlpha

Intensity Therapeutics Granted 180-Day Extension by Nasdaq to Achieve Compliance

an image of Benzinga

2025-10-31Benzinga

Dow Drops More Than 100 Points as Amazon Reports Positive Q3 Results

3 Analyst Rating

Wall Street analysts forecast INTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INTS is 3.33 USD with a low forecast of 1.50 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

1.50

Averages

3.33

High

5.00

Current: 0.000

Low

1.50

Averages

3.33

High

5.00

Benchmark

Robert Wasserman

Speculative Buy

downgrade

$4

AI Analysis

2025-08-20

Reason

Benchmark

Robert Wasserman

Price Target

$4

AI Analysis

2025-08-20

downgrade

Speculative Buy

Reason

Benchmark analyst Robert Wasserman lowered the firm's price target on Intensity Therapeutics to $1.50 from $4 and keeps a Speculative Buy rating on the shares after the company reported Q2 results and provided an update on their clinical pipeline. The firm cites recent share dilution for its revised price target.

Brookline

Hold

to

Buy

upgrade

$3

2025-08-12

Reason

Brookline

Price Target

$3

2025-08-12

upgrade

Hold

to

Buy

Reason

Brookline upgraded Intensity Therapeutics to Buy from Hold with a $3 price target following Q2 results. Raising $11M extends the cash runway to the second half of 2026, notes the firm, which also cites the advancement of the Phase 2 triple negative breast cancer trial. The firm foresees \"a favorable risk-reward as INT230-6 advances through the clinic,\" the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for INTS

Unlock Now

Valuation Metrics

The current forward P/E ratio for Intensity Therapeutics Inc (INTS.O) is -1.85, compared to its 5-year average forward P/E of -3.23. For a more detailed relative valuation and DCF analysis to assess Intensity Therapeutics Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-3.23

Current PE

-1.85

Overvalued PE

-0.98

Undervalued PE

-5.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

list of strong buy stocks under $3.00

Intellectia · 94 candidates

Price: <= $3.00Analyst Consensus: Strong Buy

Ticker

Name

Market Cap$

Akari Therapeutics PLC

9.00M

Plus Therapeutics Inc

52.00M

Reviva Pharmaceuticals Holdings Inc

38.00M

Intensity Therapeutics Inc

24.00M

Mereo BioPharma Group PLC

84.00M

Atossa Therapeutics Inc

78.00M

Whales Holding INTS

Trading Trends

People Also Watch

Frequently Asked Questions

What is Intensity Therapeutics Inc (INTS) stock price today?

The current price of INTS is 0.368 USD — it has decreased -3.67 % in the last trading day.

What is Intensity Therapeutics Inc (INTS)'s business?

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.

What is the price predicton of INTS Stock?

Wall Street analysts forecast INTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INTS is3.33 USD with a low forecast of 1.50 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Intensity Therapeutics Inc (INTS)'s revenue for the last quarter?

Intensity Therapeutics Inc revenue for the last quarter amounts to -3.00M USD, decreased -23.45 % YoY.

What is Intensity Therapeutics Inc (INTS)'s earnings per share (EPS) for the last quarter?

Intensity Therapeutics Inc. EPS for the last quarter amounts to -2387000.00 USD, decreased -39.90 % YoY.

How many employees does Intensity Therapeutics Inc (INTS). have?

Intensity Therapeutics Inc (INTS) has 5 emplpoyees as of January 29 2026.

What is Intensity Therapeutics Inc (INTS) market cap?

Today INTS has the market capitalization of 23.00M USD.